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The mechanism of action of endothehn-receptor mteractions was studied, usmg radiohgand bindmg assays and SDS-PAGE. to mvestigate the 
possibihty of dtsulfide interchange Electrophoretic analysis suggested mvolvement of disulfide bond(s) m the receptor-hgand complex. Treatment 
of Et receptors with sulthydryl-specific alkylatmg reagents (NEM or others) resulted in decreased ability to bmd [‘“SI]Et-l, [Dpr’-Asp”]Et-1, an 
antagonist homologous to Et but with an amide link replacing one of the dtsulfides, bound to Et receptors reversibly. but bindmg of Et-l was less 
reversible. Preincubation of receptors with Et-l. but not with [Dpr’-Asp”]Et-1, protected receptors from alkylation with ]“C]NEM. The data 
suggest hat the Et receptor has a sulfhydryl group at or near the Et bindmg site. A model IS proposed m which the role of the putative sulfhydryl 
group is drscussed. 
Endothelin; Eendothelm receptor: Antagonist; Mechanism 
1, INTRODUCTION 
Endothelin is a 21 amino acid vasoconstrictor peptide 
whose receptor interaction is, as yet, poorly character- 
ized. Endothelin seems to function in a regulatory role 
as a paracrine hormone synthesized primarily by endo- 
thelial cells. It regulates vascular tone through binding 
to plasma membrane receptors on local target cells [l- 
41. Receptor occupancy is reported to occur rapidly [2], 
with > 90% occupation of the available binding sites 
after a 30 s exposure to endothelin. This vasoconstrictor 
action of endothehn is a very long-lived one, as has been 
reported in a number of reviews [3,5-71. There are many 
mechanisms by which a long-lived action could be ef- 
fected, including the possibility that the ligand occupies 
the receptor for extended periods of time. Clozel et al. 
[S] reported that dissociation of the bound ligand is 
slow, with less than 10% dissociation occurring over a 
48 h period. Waggoner et al. [9] have suggested that 
Scatchard analysis of endothelin binding to receptor is 
invalid, primarily because the binding is essentially irre- 
versible. This irreversibility may be due to a covalent 
bond and this interaction may involve disulfide ex- 
change. Hagiwara et al. [IO] supported the possible in- 
volvement of disulfide exchange when they reported 
that the endothelin receptor is sensitive to the sulfhydryl 
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alkylating reagent, p-chloromercuriphenylsulfonic acid 
(PCMS). In addition, Wada et al. [ll] reported that 
endothelin-1 binding is inhibited by the heavy metal 
cadmium, an observation which could also implicate 
sul~ydryl/disuifid~ involvement. A proposed mecha- 
nism which would account for these observations is that 
the endothehn receptor may have sulfhydryl group that 
can interact with at least one of the two disulfide bonds 
of endothelin, thus forming a covalent complex. 
Recently, we described the design and synthesis of an 
endothelin-1 analog, [Dpr’-Asp’S]Et-l, in which the 
outer disulfide bond was replaced by an amide bond [I]. 
This molecule was shown to have antagonist activity 
(and no agonist activity) in a perfused lung vasocon- 
striction assay and in a bronchoconstriction assay [12]. 
It also was shown to bind to the endothelin receptor. 
although with a lower apparent affinity as compared to 
native endothelin [l]. If there is a sul~ydryl/d~sul~de 
interchange between the outer disulfide of endothelin 
and its receptor which is critical for endothelin activity, 
then this analog would be expected to bind more revers- 
ibly and to lack agonist activity. The purpose of this 
paper was to examine in greater detail the possibility 
that endothelin receptors may have critical sulfhydryl 
groups. 
2. MATERIALS AND METHODS 
Frozen Hartley gumea pjg kidneys were purchased from Keystone 
Biologicals (Cleveland. OK). [“‘I-Tyr’-‘]endothelm-I (spectfic activity 
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of 2200 Cilmmol) was obtained from New England Nuclear Research 
Products, DuPont Co. (Boston MA) and unlabeled endothelin-I was 
obtained from Peninsula Laboratories (Belmont, CA). N-Ethyl 
maleimtde. iodoacetimide, and iodoacetic acid were obtained from 
Aldrich Chemicals (Milwaukee, WI). [Dpr’-Asp”]Et-1 was synthe- 
sized as described [l]. [‘4C]N-Ethyl maleimide was obtained from 
Amersham (Arlington Heights, IL). [‘*SI]Samples were counted in a 
Auto-Gamma 5000 series counter (Umted Technologtes Packard) 
with a counting efficiency for “‘I of 88%. [?Y]Samples were counted 
in a liquid scintillation analyzer, 2000CA Tri-Carb (Umted Technolo- 
gies Packard). Results were expressed as counts per mmute (cpm). 
2.2. Methods 
treated with other sulfhydryl alkylatmg agents) was performed as in 
the [“‘Ilendothelin-1 binding studies except that membranes were 
premcubated with the indtcated concentrations of alkylating agent 
(dissolved in buffer) at room temperature for 30 mm (except as other- 
wise noted). The pH of the buffer was maintained at 7.4 with NaOH 
when preparmg the iodoacetic acid solutton. In separate experiments, 
the order of addition of N-ethyl maletmide, membrane and [“‘I]endo- 
thelin-I was varied. In one case, membranes were first preincubated 
with NEM for 1 h. In a second case, membranes were first preincu- 
bated with [“51]endothelin-l for 1 h followed by NEM for 1 h. In a 
third case, [“‘I]endothelin-1 was premcubated with NEM for 1 h 
followed by mcubation with membrane for 1 h. All incubations were 
at room temprature. 
2.2.1. Radioligand binding assays 2.2.2. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of 
Guinea pig kidney apical memhrune preparation. The method of 
Booth et al. [13] was utilized for preparation of brush-border mem- 
branes. All procedures were done m an ice bath. Membrane fragments 
were prepared from whole kidneys of Hartley guinea pigs of either sex. 
After 20 frozen kidneys had been allowed to warm at room tempera- 
ture for approximately 10 mm. the cortical tissue was carefully dis- 
sected. The cortex was then homogenized in 200 ml of IO mM manni- 
tol, 2 mM Trts-HCI, pH 7 1, at 4°C. m a Kenwood blender (model 
A 956A) run at full-speed for 2 min. The total volume of the homoge- 
nate was 400 ml. The homogenate was centrifuged on a Beckman 
Model TJ-6 centrifuge for 2 min at 200 x g (585 rpm). 
the endotheln-receptor complex 
After discarding the pellet, solid MgCI, 6H20 was added to the 
homogenate to give a concentratton of 10 mM. This solution was 
centrifuged again for 12 min at 1500 x g (2525 rpm). The pellet was 
discarded and the supernatant was centrifuged on a Sorvall RC-5B 
Refrigerated Superspeed Centrifuge with a Sorvall SS-34 Rotor for 12 
min at a K factor of 949 (13,000 rpm). The supernatant was dtscarded 
and the pellet was re-suspended in 6 ml of buffer. 100,ul aliquots were 
placed m polypropylene centrtfuge tubes and stored frozen (-70°C) 
until needed. When the membranes were used m experiments these 
aliquots were diluted to 1 ml with Hanks buffered saline (pH 7.4) 
containing 0.5 mg/ml bovine serum albumin. 
Effect of endothelin or [Dpr’-Asp”]Et-I on [“‘I]endothelm-I bmd- 
ing [“SI]Endothelln-l binding assays were performed m polypro- 
pylene centrifuge tubes. Incubation medium consisted of Hanks buff- 
ered saline (pH 7.4) containing 0.5 mglml bovine serum albumin, 
40,000 cpm [“SI]endothel~n-l, 10 ~1 of graded concentrattons of unla- 
beled ligand (endothelin or antagonist), and 5 pug membrane m a total 
volume of 0.2 ml. The tubes were incubated at room temperature for 
1 h. Incubations were terminated by filtration usmg Whatman GF/C 
filters presoaked with Hanks/albumin buffer. Ftltratton was per- 
formed on a Milhpor filtration apparatus. Filters were rinsed three 
times with 3 ml of Hanks balanced salt solutton. The filters were then 
placed in polystyrene culture tubes and counted on the gamma- 
counter. Non-specific binding was defined as the counts remaming in 
the presence of 0.2 PM endothehn-1 and was approximately 19% of 
the total bound counts. Specific binding was defined as total bmding 
minus non-specific binding. Each point represents n = 3, error bars are 
SD. 
A 100 ~1 ahquot of the guinea pig kidney apical membrane prepara- 
tion (described previously) was diluted to 1 ml in Hanks buffered 
sahne (pH 7.4) containing 0.5 mg/ml bovine serum albumin. An endo- 
thelm doseeresponse binding experiment was carried out m duplicate, 
using 10~1 ofmembrane dilution, 10~1 ofgraded endothehn-1 concen- 
trations, 50 ~1 of [“‘I]endothelin-1 (15 PM), and brought to a total 
volume of 0.2 ml with Hanks buffer. The tubes were allowed to 
incubate at room temperature for 1 h. Two sample buffer solutions 
were prepared, one containing 2-mercaptoethanol (‘reducing buffer’) 
and one without 2-mercaptoethanol (‘non-reducing buffer’). The non- 
reducing buffer contamed 4.7 ml of distilled water, 1.0 ml of 0.5 M 
Tris-Cl, pH 6.8. 1.0 ml of glycerol, 1.0 ml of 10% (w/v) SDS, 0.2 ml 
of 0.05% Bromophenol blue, with the addition of 0.1 ml of 2-mercap- 
toethanol in the reducing buffer. 
After the binding experiments were completed, the reaction mix- 
tures were centrifuged at 10.000 x g for 10 min at 4°C. The pellets were 
rinsed and centrifuged two more times with 1 ml of the Hanks/albumin 
buffer. 50 ~1 of non-reducing buffer was added to one sample from 
each duphcate while the other sample had 50~1 reducing buffer added. 
These pellets were solubilized in the buffer and allowed to mcubate at 
37°C for I h, then subJected to electrophorests. The gel was then 
subJected to autoradiography using the X-Omat AR film for 7 days 
t -70°C 
“I 
3. RESULTS 
3.1. Radioligand binding assays 
3.1.1. Effect of endothelin-1 or [Dpr’-Asp”]Et-1 on 
[“‘Ilendothelin-1 binding 
Effect of endothelm or [Dpr’-AspJ5/Et-1 on [“C]N-ethyl malermtde 
bindmg. [‘4C]N-Ethyl maleimide binding assays were performed m 
polypropylene centrifuge tubes. Membranes (10 pg) were first treated 
with graded concentrations of endothehn or antagonist for 1 h. then 
100,000 cpm [?]NEM were added m a medium consisting of Hanks/ 
albumin buffer, total volume of 0.2 ml. The tubes were incubated at 
room temperature for 1 h. Incubations were terminated by spurning 
on a Beckman Microfuge at 12.000 rpm for 15 mm. Supernatant was 
removed and discarded and pellet was resuspended in 1 ml of buffer. 
This solution was spun at 12,000 rpm for 15 min. The supernatant was 
again removed and discarded and the pellet was resuspended in 100 
~1 of 1 N NaOH. Each tube was rinsed mto the liquid scintillation vials 
contaming 5 ml of scmtillation thud. 
Effect of sul@ydryl alkylatmg reugents on [““I]endothelm-1 bmdmg. 
Binding to N-ethyl maleimide treated membranes (or membranes 
Fig. 1A indicates that [Dpr’-Asp”]Et-1 effectively 
competed with [‘251]endothelin-l for binding to guinea 
pig kidney membrane preparation. although with a po- 
tency of about two orders of magnitude less than did 
unlabeled endothelin-1. A time course study was done 
to test the reversibility of the endothelin-receptor inter- 
action (Fig. IB). The control series exhibited essentially 
full binding of [‘251]endothelin-l within minutes of addi- 
tion of the radioligand. Preincubation of receptor (in 
guinea pig kidney membrane) with unlabeled endothe- 
lin ( 10m9 M, close to its IC,,J for 1 h effectively prevented 
the binding of [‘251]endothelin-l. The structural analog 
[Dpr’-Asp”]Et-1 (at a dose well above its IC,,, 10m6 M) 
substantially blocked [“‘Ilendothelin-1 binding ini- 
tially, but over the course of several minutes, [lz51]endo- 
thelin-I binding increased to control levels. This sug- 
gested a largely irreversible interaction between endo- 
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allowed for decreased uptake of [“CINEM. whereas the 
analog at doses as high as IO-’ M was unable to prevent 
uptake of the labeled sulfhydryl alkylating agent (Fig. 
2). Endothelin, at any concentration tested, could not 
prevent totally the uptake of [“CINEM. suggesting that 
sulfhydryl groups other than endothelin-receptors were 
being alkylated. 
3.1.3. Effect of sulfhydryl alkylating reagents on 
[“51]endothelin-l binding 
Fig. 3A shows the results of alkylation with N-ethyl 
maleimide when the receptor was pretreated with in- 
creasing concentrations of NEM at room temperature 
for 30 min, then allowed to bind [“‘I]endothelin-1 for 
1 h (solid line), the results was a diminished capacity to 
bind endothelin. The dashed line shows the effects on 
binding when the receptor was pretreated with [“‘Ilen- 
dothelin-1, then subjected to the indicated doses of 
NEM. No loss of endothelin binding was noted. The 
dotted line is a control in which endothelin was preincu- 
bated with the indicated doses of NEM and then the 
mixture was added to the receptor. In Fig. 3B, receptor 
was pretreated with various sulfhydryl alkylating rea- 
gents (1 x lo-’ M) at room temperature for 30 min, then 
allowed to bind [“‘I]endothelin-1 for 1 h. NEM exhib- 
ited the greatest inhibition of [“51]endothelin-l binding. 
This may have resulted from a decrease in the number 
of viable receptors available. In contrast, iodoacetamide 
(IAM) had little effect on binding of endothelin. These 
Fig. 1. Receptor-hgand interactions. Fig. 1A shows the results of a 
competltlve ra&ohgandPreceptor assay. [““I]endothelm-1 (40 x 10’ 
cpm. specific activity 2200 Ci/mmol) and gumea pig kidney aplcal 
membranes (10 pg) were Incubated hith the indicated amounts of 
endothelin-I (circles) or [Dpr’-Asp”]Et-1 (triangles) in a total volume 
of 0.3 ml for 1 h at room temperature. Data are the mean i: S.D. of 
triphcate determinations wlthm one assay; the assay was repeated 3 
times with two different receptor preparations. Fig. IB 1s a time course 
of bindmg of [““Ilendothelm-1 after premcubating receptor with 
1 x IO-’ M endothehn-I (open circles), 1 x IO-” M [Dpr’-Asp”]Et-1 
(triangles), or buffer (filled circles). 
thelin and its receptor in comparison to a reversible 
interaction between [Dpr’-Asp”]Et-1 and the endothe- 
lin receptor. 
3.1.2. Effect of endothelin-1 or [Dpr’-Asp’5]Et-l on 
[‘%]N-ethyl maleimide binding 
In order to demonstrate further the reversible nature 
of binding for the analog [Dpr’-Asp’“]Et-1 in compari- 
son to the irreversibility of endothelin- 1 binding, recep- 
tors were pretreated for 1 h with various concentrations 
of unlabeled endothelin or unlabeled [Dpr’-Asp”]Et-1. 
Subsequently, [14C]NEM was added and allowed to in- 
cubate for 1 h. Increasing concentrations of endothelin 
i 
-I 
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Fig. 2 Uptake of [14C]NEM by endothelin receptors. [“C]NEM bmd- 
mg to gumea pig kidney aplcal membranes pretreated with mdlcated 
doses of endothelm-1 (open circles) and [Dpr’-Asp”]Et-1 (filled clr- 
cles) indicates that increasmg concentrations of endothehn. but not of 
[Dpr’-Asp”]Et-1, were able to prevent the uptake of radlolabeled 
NEM. Values given as percent of maxlmal bmdmg Each data pomt 
represents the mean ? S.D. of trlphcate determinations from a repre- 
sentatlve experiment 
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Fig. 3. Alkylation of receptor with N-ethyl maletmide (A) Order of 
addition: the solid line shows the effects on binding when receptor was 
preincubated with the indicated doses of NEM, then allowed to bind 
[‘“51]endothelm-l The dashed line shows the effects on bmding when 
the receptor was pretreated with [“SI]endothelin-l, then subjected to 
the indicated does of NEM. The dotted hne is a control m which 
endothelin was preincubated wtth the indicated doses of NEM and 
then the mixture was added to the receptor. (B) Receptor was pre- 
treated wtth 1 x lo-’ M of the various sulfhydryl alkylating reagents 
at room temperature for 30 min. then washed and allowed to bind 
[“51]endothehn-l for 1 h. Values are given as percent of maximal 
binding. Maximal binding was defined separately for each treatment 
as binding m absence of alkylatmg agent (approx. 9000 cpm). Each 
data point represents the mean k S.E.M. of triplicate determmations 
from a representative experiment. 
results imply that NEM and IAA bind to sulfhydryls on 
endothelin receptors and are successful in blocking 
binding of [“‘Ilendothelin-1. IAM likely binds to 
sulfhydryls on endothelin receptors but is not able to 
prevent [“51]endothelin-l binding. 
3.2. SDS-PAGE of the endothelin-receptor complex 
[“51]Endothelin-l was allowed to bind to receptor 
preparations, followed by dissolution in either non-re- 
ducing or reducing buffer. Samples were then subjected 
to electrophoresis and Fig. 4 shows the autoradiogram. 
In the absence of reducing agents, a single band is ob- 
served at high molecular weight (t 100 kDa). However, 
upon reduction, the high molecular weight band disap- 
pears and there is probably a slight increase in the den- 
sity of the band at 2500 Da (representing endothelin). 
From the reported cloning of the ET, receptor 
[14-l 51, and from the electrophoretic studies [l&l 81 in 
which endothelin-I was covalently cross-linked to re- 
ceptor and then treated with reducing buffer, it was 
expected that a band at approximately 50 kDa would 
be observed. In the autoradiograph, faint middle bands 
are present which are approximately 50 kDa, but the 
majority of the label is at higher molecular weight. 
Whether these bands truly represent endothelin recep- 
tors remains to be determined, but in this study, in 
which non-reducible cross-linking techniques were not 
used, it may be suggested that these bands represent 
receptor subunits that interact through disulfide bonds. 
4. DISCUSSION 
Several observations in the literature, when taken to- 
gether, could suggest that endothelin receptors interact 
with their ligand through sullhydryl/disulfide inter- 
change. Among these observations are those of Wag- 
goner et al. suggesting that endothelin binding is largely 
irreversible [9], of Hagiwara et al. suggesting that p- 
chloromercuriphenylsulfonic acid (PCMS) inactivates 
endothelin receptors [lo], and of Wada et al. which 
indicates that the heavy metal cadmium inactivated 
ET receptors [l 11. Further, we have shown that 
[Dpr’-Asp”]Et-1. a structural analog of endothelin 
which has an amide bond replacing one of its disulfide 
bonds, is an endothelin antagonist. However, one of its 
analogs, a monocyclic derivative which lacks the amide 
bond is a weak agonist. In addition, the reported se- 
quences of the ET, and ET, receptors demonstrate that 
there are 19 Cys in total, probably arranged as 4 on the 
cytoplasmic side. 7 in the membrane-spanning region, 
and 8 internal. One or more of these residues could 
possibly interact with a disulfide of endothelin. There- 
fore, we sought to test the possibility in a more direct 
fashion, employing standard alkylation studies, ligand 
binding studies. and electrophoretic analysis. 
Alkylation of receptors with N-ethyl maleimide re- 
sulted in a loss of binding of endothelin, and this de- 
crease was dependent on the concentration of NEM 
or the time of incubation with NEM. Conversely, incu- 
bation of receptor with endothelin, but not with 
[Dpr’-Asp’5]Et-l, decreased the uptake of [‘“C]NEM by 
receptor preparations. Total blockage was not observed 
in these crude membrane fractions, undoubtedly be- 
cause sulfhydryls exist on protein other than the endo- 
thelin receptor. These data would suggest that the endo- 
thelin receptor may contain one or more sulfhydryl 
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Fig 4. Effect of sodium dodecyl sulfate-polyacrylamide gel electrophoresls on [‘251]endothelin-l~receptor interaction. [“I]Endothelm-1 bmdmg 
to guinea pig kidney apical membranes in the presence of graded concentrations of unlabeled endothehn-I (1 x lO_‘” to I x 10mh M). Lanes 1 to 
6 represent an endothehn-1 dose-response curve subjected to non-reducmg conditions after [“51]endothelm-l bindmg was completed. Lanes 8 to 
13 represent an endothehn-1 dose response curve subjected to reducmg con&ions after [“SI]endothehn-l bmdmg was completed. 5 ,uI of molecular 
mass standard was placed m lane 7 for determination of the )2fr. 
groups which are sensitive to alkylation. That endothe- 
lin can block uptake of NEM suggests that a sulfhydryl 
may be near the ligand binding site, though further 
work would be needed to confirm this unequivocally. 
Further observations concerning the alkylation stud- 
ies are of interest. First, fairly high concentrations of 
NEM were required for maximal loss of endothelin 
binding, and this may suggest that the putative sulfhy- 
dry1 is not easily accessible to a bulky group such as 
NEM. This led to the use of alternative alkylating 
agents and to the second observation. Iodoacetic acid 
(IAA) and iodoacetamide (IAM) were employed be- 
cause they are smaller than NEM. However, only IAA 
blocked endothelin binding. Likely mechanisms for this 
observation include the possibility that IAM did not 
alkylate the receptor, which seems unlikely, or that the 
small size and lack of charge on IAM allowed endothe- 
lin to bind. That is to say, it may be that the larger size 
of NEM and the charge of IAA interfere with binding 
(Table I). No biological studies were employed with 
these toxic alkylating agents for obvious reasons, but it 
Table I 
Physical properties of sulfhydryl alkylating reagents and their elfect 
on [““I]endothelin-l-receptor bmding 
Reagent 
Iodoacetic acid 
Iodoacetamlde 
N-Ethylmaleimide 
86 
Physlcal propertles Effect on 
endothehn bmding 
Small; charged Decreases 
Small; uncharged None 
Large; uncharged Decreases 
may be that endothelin bound to IAM-alkylated recep- 
tors would be unable to cause the normal signal 
transduction. 
Electrophoretic analysis using radiolabeled endothe- 
lin resulted in the observation of high molecular weight 
bands which may represent endothelinPreceptor com- 
plexes. These bands were not detected in the presence 
of reducing agents, implicating disulfide interchange. If 
these bands do represent endothelin receptors, which 
have a molecular weight near 50 kDa [14,15], then they 
must have been aggregated in a manner that can be 
overcome by the addition of reducing agents. Other 
workers have not reported such an observation, but 
most have employed photoactively-crosslinked endo- 
thelin receptor complexes in the presence of reducing 
agents. These conditions would lead to identification of 
the 50 kDa polypeptide, but not to larger molecular 
weight complexes. 
A model for the interaction of endothelin with 
its receptor can be proposed which is consistent with all 
the data and which offers new leads on the nature of the 
interaction and the nature of the antagonist, 
[Dpr’-Asp”]Et-1. As shown in Fig. 5, the antagonist 
properties [l] of [Dpr’-AspiSlEt- suggest that there are 
two distinct endothelin conformations. A ‘receptor 
binding’ conformation is depicted as a bicyclic struc- 
ture, and this conformation may or may not be the 
solution structure of endothelin, but if it is not the solu- 
tion structure, it is some conformation easily accessible 
to the molecule. A ‘receptor activating’ conformation is 
proposed to be a more open. monocyclic structure. It 
is proposed that these two structures can interconvert 
Volume 328, number 1.2 FEBS LETTERS August 1993 
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Fig. 5. Proposed model for endothelin-receptor interactions 
by means of disulfide interchange with the receptor. 
[Dpr’-Asp”]Et-1 is depicted as being ‘locked’ in the 
receptor binding confo~ation, unable to achieve the 
receptor activating conformation because it has an 
amide bond instead of the outer disulfide bond of endo- 
thelin. Thus [Dpr’- Asp”]Et-1 can bind to receptor but 
not interact with the receptor through disulfide ex- 
change in order to generate the flexibility necessary to 
achieve receptor activation. Other conformationally 
constrained antagonists [19,20] have been reported, and 
it may be that these molecules are similarily unable to 
achieve the flexibility required for receptor activation. 
As shown previously [I], a control peptide is devoid of 
an outer disulfide bond, and is depicted as an open, 
monocyclic structure. A small percentage of the mon- 
ocyclic peptide molecules may approximate the bicyclic. 
receptor binding conformation even though there is no 
outer bridge. Once bound to the receptor, the monocy- 
clic peptide is flexible enough to assume the receptor 
activating conformation, circumventing the disulfide 
exchange requirement. This is an important distinction. 
The model proposes that it is not a disulfide bonded 
complex between endothelin and receptor, per se, that 
is responsible for receptor activation, but that disulfide 
exchange is a necessary intermediate step for endothelin 
to achieve receptor activation. This may explain the 
weak agonist activity [l] of the monocyclic peptide and 
similar monocyclic analogs reported in the literature 
[193_ When the receptor is first treated with NEM or 
other sul~ydryl alky~ating reagents, the ‘critical’ free 
sulfhydryl at the ligand binding site becomes blocked, 
leading to a decrease in receptor binding through steric 
or charge effects. Although not tested in this work due 
to the expected toxicity of alkylating reagents, endothe- 
lin binding to modified receptors would be predicted by 
this model to be biologically inactive. This could best 
be tested using site-directed mutagenesis of the endothe- 
lin receptor. 
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